## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.15 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-6.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($649.50)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Regeneron Reports Promising Results from LINKER-MM4 Trial of Lynozyfic™ for Newly Diagnosed Multiple Myeloma**
- Source: Quiver Quantitative | 20251207T220841 | Somewhat-Bullish | Relevance: 100%
-  Regeneron Pharmaceuticals announced promising interim results from its Phase 1/2 LINKER-MM4 trial for Lynozyfic™ (linvoseltamab) in adults with newly diagnosed multiple myeloma. The trial showed that all dose groups achieved a very good partial response or better (VGPR+) of ≥70%, with a high rate of minimal residual disease negative status. Regeneron will host a virtual investor event on December 10, 2025, to discuss its multiple myeloma development program further, highlighting the drug's potential as a foundational component for frontline treatment.

**2. Natixis Purchases 2,751 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251208T130838 | Somewhat-Bullish | Relevance: 99%
- Natixis increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 4.0% in the second quarter, acquiring an additional 2,751 shares to hold a total of 72,180 shares valued at approximately $37.9 million. Other institutional investors like Bank of Nova Scotia, Federated Hermes Inc., and Marshall Wace LLP also significantly boosted their holdings. The biopharmaceutical company recently reported strong quarterly earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating with an average target price of $777.36.

**3. 14 Best US Stocks to Buy for Long Term**
- Source: Insider Monkey | 20251208T070855 | Bullish | Relevance: 99%
- This article identifies top US stocks for long-term investment, focusing on Regeneron Pharmaceuticals (NASDAQ: REGN) as an example. It details Regeneron's financial performance, analyst ratings, and a new gene therapy collaboration, highlighting factors that make it a promising long-term holding.

**4. Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating**
- Source: Insider Monkey | 20251208T171843 | Bullish | Relevance: 98%
-  BMO Capital has reiterated its Outperform rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and increased its price target to $850 due to the company's strong recovery, anticipated better performance from Dupixent, and a slower decline in Eylea sales. This positive outlook follows a significant stock surge after a previous setback, indicating renewed confidence in Regeneron's pipeline and market position. The company also announced a collaboration with Tessera Therapeutics for a new gene therapy, TSRA-196, for alpha-1 antitrypsin deficiency.

**5. ASH takeaways: Regeneron unveils new data on blood cancer drugs, touts hematology pipeline**
- Source: Medical Marketing and Media | 20251209T161534 | Bullish | Relevance: 98%
-  Regeneron presented new early data on two of its blood cancer drugs, linvoseltamab and odronextamab, at the American Society of Hematology (ASH) annual conference. Linvoseltamab showed efficacy as a monotherapy in newly diagnosed multiple myeloma, with a 70% very good or partial response rate. Odronextamab, in a trial combining it with CHOP chemotherapy for diffuse large B-cell lymphoma, achieved a 100% complete response rate among 13 patients.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |
| 2025-11-24 | Scotiabank | $770 | $650 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |
| 2025-11-24 | Scotiabank | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($20.86M) |
| Sells | 5 ($11.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $11M sold (5 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +18%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (4 raises, avg +18%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.4B |
| Beta | 0.37 |
| 52W Range | $476.49 - $791.49 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 17.5 |
| Current P/E | 16.0 |
| YoY Growth | -8.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -0.7% to -6.8% (-6.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.8pp (needs >4.0% for momentum thesis). AM_20 at -4.7% indicates price below own 20MA trend. Long-term uptrend intact (above SMA200 at 1.16x) but short-term weakness (below SMA20). MACD histogram bearish (-10.96), momentum weakening. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.76% (CS: 7) | Weak |
| RSI_14 | 46.7 | Neutral |
| MACD Histogram | -10.96 | Bearish |
| vs SMA20 | 0.953x | Below |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 1.156x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $692.58
- **Stop Loss:** $649.50 (6.2% risk)
- **Target:** $778.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 6
- **Position Value:** $4,155.48
- **Portfolio %:** 4.16%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*